Pharmaceutical News

RSS

Technique for developing more targeted drugs using molecular "robots"

Many drugs such as agents for cancer or autoimmune diseases have nasty side effects because while they kill disease-causing cells, they also affect healthy cells. Now a new study has demonstrated a technique for developing more targeted drugs, by using molecular "robots" to hone in on more specific populations of cells.

29 Jul 2013

GlaxoSmithKline receives CHMP positive opinion for REVOLADE

Ligand Pharmaceuticals Incorporated partner GlaxoSmithKline announced that today, the European Medicines Agency's Committee for Medicinal Products for Human Use issued a positive opinion recommending marketing authorization for GSK's REVOLADE (eltrombopag) as a treatment for low platelet counts (thrombocytopenia) in adult patients with chronic hepatitis C infection, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy

26 Jul 2013

FDA grants orphan-drug designation for Ligand’s Captisol-enabled Topiramate Injection

Ligand Pharmaceuticals Incorporated announced that the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation for its proprietary Captisol-enabled Topiramate Injection for the treatment of partial onset or primary generalized tonic-clonic seizures in hospitalized epilepsy patients who are unable to take oral topiramate.

26 Jul 2013

Compliance leaders give insight and thoughts in new ebook

Regulatory non compliance costs the pharma industry billions in fines, audits and much more each year. To avoid these fines and bad reputation pharma companies rely heavily on their compliance teams, who provide oversight from R&D to the very end of a product cycle.

26 Jul 2013

FDA acknowledges receipt of NDA resubmission of dapagliflozin drug for treatment of type 2 diabetes

AstraZeneca (NYSE: AZN) and Bristol-Myers Squibb Company (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of the New Drug Application (NDA) resubmission for investigational drug dapagliflozin for the treatment of adults with type 2 diabetes.

26 Jul 2013

Rapamycin extends mice lifespan but has limited effects on aging

The body's repair mechanisms begin to fail with increasing age. As a result, signs of wear and tear appear and the risk for many diseases, including Alzheimer's disease, diabetes, cardiovascular disorders and cancer, increases.

26 Jul 2013

New research provides insight into mechanisms, action of Radix Achyranthis Bidentatae

A research team from the School of Basic Medical Sciences, Beijing University of Chinese Medicine reports that Radix Achyranthis Bidentatae can inhibit advanced glycation end product formation, reduce their levels in the frontal cortex, and improve learning and memory capabilities in ovariectomized rats.

26 Jul 2013

Epigenetic changes induced by ADO therapy prevent epilepsy progression

Epilepsy is characterized by recurrent seizures that present in many different ways. In some cases epileptic patients exhibit a progressive increase in both frequency and severity of seizures. Epigenetic changes such as DNA methylation have recently been implied as an underlying cause of several neurologic disorders, including epilepsy.

26 Jul 2013

Forest Laboratories, Pierre Fabre Laboratories announce that FETZIMA gets FDA approval for MDD

Forest Laboratories, Inc. and Pierre Fabre Laboratories announced today that FETZIMA (levomilnacipran extended-release capsules), a once-daily serotonin and norepinephrine reuptake inhibitor, discovered by Pierre Fabre Laboratories and co-developed by Forest Laboratories, Inc. was approved by the U.S. Food and Drug Administration for the treatment of Major Depressive Disorder in adults.

26 Jul 2013

Zydus, IDRI partner to develop visceral leishmaniasis vaccine candidate

In a unique partnership, Zydus, India's fourth largest healthcare group and an innovation-led global healthcare provider, and IDRI, a Seattle-based non-profit research and product development organization, announced today they are collaborating on the production and clinical development of IDRI's visceral leishmaniasis vaccine candidate, designed to prevent the deadly parasitic disease.

26 Jul 2013

Researchers explain how gut bacteria can inactivate cardiac drugs

For decades, doctors have understood that microbes in the human gut can influence how certain drugs work in the body - by either activating or inactivating specific compounds, but questions have long remained about exactly how the process works.

26 Jul 2013

First lots of 2013-2014 seasonal influenza vaccine released for U.S. distribution

Sanofi Pasteur, the vaccines division of Sanofi, announced today that the first lots of Fluzone (Influenza Virus Vaccine) for the 2013-2014 season have been released by the U.S. Food and Drug Administration for U.S. distribution and were shipped July 24.

25 Jul 2013

Study: Daily dietary supplementation with blend of omega fatty acids improves severe dry eye

Study findings published online, ahead of print, in Cornea show that daily dietary supplementation with a unique combination of omega fatty acids (GLA, EPA and DHA) for six months is effective in improving ocular irritation symptoms and halting the progression of inflammation that characterizes moderate to severe dry eye.

25 Jul 2013

Novo Solutions MD announces releases of NovoScarMD scar cream

Novo Solutions MD announces the launch of NovoScarMD the most scientifically advanced scar cream to come to market in 10 years. NovoScarMD reverses existing and new scar damage, keloids, and stretch marks, and rapidly returns skin to its original state with almost no trace of skin injury

25 Jul 2013

Mylan, Orion sign settlement, license agreement for generic version of STALEVO

Mylan Inc. today confirmed that Mylan Pharmaceuticals Inc. and Orion Corporation have entered into a settlement and license agreement settling the parties litigation in connection with Mylan's filing of an Abbreviated New Drug Application with the U.S. Food and Drug Administration for Carbidopa/Levodopa/Entacapone Tablets, 12.5 mg/50 mg/200 mg, 18.75 mg/75 mg/200 mg, 25 mg/100 mg/200 mg, 31.25 mg/125 mg/200 mg, 37.5 mg/150 mg/200 mg, and 50 mg/200 mg/200 mg.

25 Jul 2013

Combination treatment can reduce hepatitis C infection in people who inject drugs

The burden of liver disease could be dramatically reduced by scaling up the combination of interventions for hepatitis C infection among people who inject drugs according to University of Bristol researchers. The findings, published today [24 July], form part of new global recommendations on treating the virus.

25 Jul 2013

Stopping cholesterol drugs may increase risk of Parkinson's disease

People who stop taking cholesterol drugs may be at an increased risk for developing Parkinson's disease, according to research that appears in the July 24, 2013, online issue of Neurology, the medical journal of the American Academy of Neurology.

25 Jul 2013

Ligand Pharmaceuticals, Ethicor Pharma sign license agreement for lasofoxifene

Ligand Pharmaceuticals Incorporated announces the signing of a license agreement with Ethicor Pharma Ltd. for the manufacture and distribution of the oral formulation of lasofoxifene in the European Economic Area, Switzerland and the Indian Subcontinent.

24 Jul 2013

Verastem's defactinib gets FDA orphan drug designation for treatment of mesothelioma

Verastem, Inc., focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced that lead cancer stem cell inhibitor, VS-6063 (defactinib), has received orphan drug designation from the U.S. Food and Drug Administration for use in the treatment of mesothelioma, a rare form of lung cancer.

24 Jul 2013

Mylan Pharmaceuticals agrees to resolve patent litigation related to Erlotinib Hydrochloride Tablets

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has entered into a settlement agreement with OSI, Pfizer and Genentech that will resolve patent litigation related to Erlotinib Hydrochloride Tablets, 25 mg, 100 mg and 150 mg.

24 Jul 2013

Pharmaceutical News

Technique for developing more targeted drugs using molecular "robots"

GlaxoSmithKline receives CHMP positive opinion for REVOLADE

FDA grants orphan-drug designation for Ligand’s Captisol-enabled Topiramate Injection

Compliance leaders give insight and thoughts in new ebook

FDA acknowledges receipt of NDA resubmission of dapagliflozin drug for treatment of type 2 diabetes

Rapamycin extends mice lifespan but has limited effects on aging

New research provides insight into mechanisms, action of Radix Achyranthis Bidentatae

Epigenetic changes induced by ADO therapy prevent epilepsy progression

Forest Laboratories, Pierre Fabre Laboratories announce that FETZIMA gets FDA approval for MDD

Zydus, IDRI partner to develop visceral leishmaniasis vaccine candidate

Researchers explain how gut bacteria can inactivate cardiac drugs

First lots of 2013-2014 seasonal influenza vaccine released for U.S. distribution

Study: Daily dietary supplementation with blend of omega fatty acids improves severe dry eye

Novo Solutions MD announces releases of NovoScarMD scar cream

Mylan, Orion sign settlement, license agreement for generic version of STALEVO

Combination treatment can reduce hepatitis C infection in people who inject drugs

Stopping cholesterol drugs may increase risk of Parkinson's disease

Ligand Pharmaceuticals, Ethicor Pharma sign license agreement for lasofoxifene

Verastem's defactinib gets FDA orphan drug designation for treatment of mesothelioma

Mylan Pharmaceuticals agrees to resolve patent litigation related to Erlotinib Hydrochloride Tablets

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News